Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis. - Wikidata - wikimedia - TriplyDB

Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis.

Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis.

http://www.wikidata.org/entity/Q37544674

about

An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.Targeted brain delivery nanoparticles for malignant gliomas.Nanomedicines for renal disease: current status and future applications Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis.Novel biodegradable nanocarriers for enhanced drug delivery.Specialized pro-resolving mediators in cardiovascular diseases.Traditional Chinese Medicine Protects against Cytokine Production as the Potential Immunosuppressive Agents in Atherosclerosis.Targeted nanoparticles for colorectal cancer.Development of mannose functionalized dendrimeric nanoparticles for targeted delivery to macrophages: use of this platform to modulate atherosclerosis.Multiscale technologies for treatment of ischemic cardiomyopathy.Recent Advances in Managing Atherosclerosis via Nanomedicine.Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr-/- Mice.Kinin B1 receptor as a novel, prognostic progression biomarker for carotid atherosclerotic plaques.Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis.Methotraxate-Loaded Hybrid Nanoconstructs Target Vascular Lesions and Inhibit Atherosclerosis Progression in ApoE-/- Mice.The Multifaceted Uses and Therapeutic Advantages of Nanoparticles for Atherosclerosis Research.A review on core-shell structured unimolecular nanoparticles for biomedical applications

P2860

Q37282266-C73DF556-68CA-43D5-9F37-B49DFF839C47 Q38681468-A8FDC5FF-023E-492D-93B5-EAC5B5198FFD Q38791884-8275E09F-EE46-4FAB-9DF7-659898FCA46C Q38802375-B59CB741-85F5-4916-A8B2-BE957D5E7CE6 Q38828033-94382529-1E74-4C04-961B-9CF79EE9793F Q39005331-F9EE5C75-9E24-446A-A3A2-90A4839A3B56 Q39160278-239E8221-8286-4009-889A-10236C675AC9 Q42361233-B11A208C-39D8-4BAF-BEBD-B73CF2E45A7A Q42365964-BCBFBC44-2C57-420B-8837-E1F4D7B28026 Q45073834-E335D452-AF61-43C1-8890-AE7A5C32F04D Q46454164-B45977CF-F719-4F54-A684-24852D5D9723 Q47251361-064D6B37-F161-4962-9E49-E4D28FB5D1D6 Q47898903-0D081473-66EC-4E92-97FC-59ABB230253E Q47909309-38C4AE71-C8E9-4241-8E99-8680F36EA2B6 Q49318594-4F6B9938-37FF-4D84-9E29-B7F306B14072 Q50659065-FC25B2D7-F1F7-4CBE-B02A-AB436E1A0184 Q54402965-78A505DC-665B-4948-9624-FDABC84D6A00 Q57179221-713E8425-F999-4168-A2AE-14A4AF20F281

P2860

Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis.

http://www.wikidata.org/entity/Q37544674

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeted Interleukin-10 Nanoth ...... n in Advanced Atherosclerosis.

@en

Targeted Interleukin-10 Nanoth ...... n in Advanced Atherosclerosis.

@nl

type

label

Targeted Interleukin-10 Nanoth ...... n in Advanced Atherosclerosis.

@en

Targeted Interleukin-10 Nanoth ...... n in Advanced Atherosclerosis.

@nl

prefLabel

Targeted Interleukin-10 Nanoth ...... n in Advanced Atherosclerosis.

@en

Targeted Interleukin-10 Nanoth ...... n in Advanced Atherosclerosis.

@nl

P1433

Q37544674-D7DA9C68-AC46-434D-A908-2940DF4B53FB

P1476

Q37544674-60DE135D-05CB-445D-9C5C-B252D817C3C7

P2093

Q37544674-0A7BEEDD-099A-4265-9B37-14472FD4D14B

Q37544674-1773E138-A065-4A35-9231-7741F6067E3F

Q37544674-2575EFF0-6462-428B-98EB-D0E899CD260E

Q37544674-2C788FD9-343D-4AF2-A422-8589CB981B27

Q37544674-4881AA6E-F2B2-4FE7-BEDA-1C795B7593F3

Q37544674-5CC242D2-CF06-4D12-8C70-67DED0DA634E

Q37544674-5CD0C8C4-429C-4C53-9AFA-0E2C4FD8536E

Q37544674-70175389-8F2A-4016-8025-A25002EBBC53

Q37544674-770063B9-A356-4BA4-A644-264829F3CA41

Q37544674-9025D471-44D8-460E-997D-301ABEF504CA

P2860

Q37544674-03DCB914-1AC1-4572-B761-A87E7F28FB3C

Q37544674-0754CFE2-1CA9-4803-88D6-4F3263ED869E

Q37544674-07D82ABE-E818-4A80-8D55-AC7B79AC50B0

Q37544674-0BCDFD48-D359-4E76-AE8C-0C421E499A62

Q37544674-0E70AAB2-27FB-4CEF-B753-81B907D93078

Q37544674-0F0B6B39-86D1-49FC-B6AC-8E521CB1EFEA

Q37544674-191D4705-4CD3-426C-A989-CF48B5E49A60

Q37544674-2035DD9C-2D2D-439D-9121-DE65923D6C49

Q37544674-2485A7CC-76E5-4248-A139-5BA7E2B06BE3

Q37544674-293E583E-2EFD-4ECE-9BC3-B768F33EC7C9

P304

Q37544674-167D744B-42CD-486A-BAF1-D2192F68D3C2

P31

Q37544674-0A28E8F9-0D6B-4FF0-BCA2-27BF46E34191

P356

Q37544674-8ED7AF39-4F95-45F2-A342-096625CE3B05

P407

Q37544674-F2428512-3CD8-496F-B6DA-611175339C85

P433

Q37544674-50F94D66-1AD0-4D87-84C4-76DB3B45D018

P478

Q37544674-7EDE2F7D-A922-4D42-858F-816E44032DF3

P50

Q37544674-235A10DC-7217-42DF-9816-017C756457B0

Q37544674-9292FC16-01FF-4568-A8E1-0ED05F005FA4

Q37544674-99D5431D-AA7E-4BCE-AEF8-609F15C8C1BB

Q37544674-9D318B7F-9BE6-4AA7-91DB-E586EE61608A

Q37544674-F8774C95-F339-450E-AB97-D0283F8B0C83

P577

Q37544674-B76DBF4A-3193-4080-84CC-9DEFEA4BE4FB

P698

Q37544674-60B580C3-0703-49C2-87CF-7DF12252424C

P921

Q37544674-49D40E62-6428-4F04-A4DB-ECF8CBFA4174

Q37544674-5DC8E374-18F8-44B6-866E-5E4C460C17E6

Q37544674-DF79E675-2BAC-467D-8F9D-AF4B66A9923A

Q37544674-c2a5ee56-1ad7-43b7-ab7f-4155f2e2a703

P932

Q37544674-5F0096DA-6F65-4361-B6E2-BC95F59D98B5

P356

ACSNANO.6B01114

P1433

P1476

Targeted Interleukin-10 Nanoth ...... on in Advanced Atherosclerosis

@en

P2093

Gabrielle Fredman

http://www.w3.org/2001/XMLSchema#string

Huayi Gao

http://www.w3.org/2001/XMLSchema#string

Ira Tabas

http://www.w3.org/2001/XMLSchema#string

Jaclyn Milton

http://www.w3.org/2001/XMLSchema#string

Jhalique Jane R Fojas

http://www.w3.org/2001/XMLSchema#string

Jordan Harris

http://www.w3.org/2001/XMLSchema#string

Jun Wu

http://www.w3.org/2001/XMLSchema#string

Katherine Zepeda

http://www.w3.org/2001/XMLSchema#string

Manikandan Subramanian

http://www.w3.org/2001/XMLSchema#string

Mikyung Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-10 and the interleukin-10 receptor

Anti-inflammatory therapy in chronic disease: challenges and opportunities

Imaging and nanomedicine in inflammatory atherosclerosis

Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?

Homeostasis, inflammation, and disease susceptibility

Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19

Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications

Annexin A1 and glucocorticoids as effectors of the resolution of inflammation

Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma

Macrophages in the pathogenesis of atherosclerosis

P304

5280-5292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSNANO.6B01114

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Omid C. Farokhzad

Livia Rosa-Fernandes

P577

2016-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27100066

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

5199136

http://www.w3.org/2001/XMLSchema#string